Display options
Cite
Moisoiu V, Teodorescu P, Parajdi L, et al. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the . Front Oncol. 2019;9:863doi: 10.3389/fonc.2019.00863.
Moisoiu, V., Teodorescu, P., Parajdi, L., Pasca, S., Zdrenghea, M., Dima, D., Precup, R., Tomuleasa, C., & Soverini, S. (2019). Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the . Frontiers in oncology, 9863. https://doi.org/10.3389/fonc.2019.00863
Moisoiu, Vlad, et al. "Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the ." Frontiers in oncology vol. 9 (2019): 863. doi: https://doi.org/10.3389/fonc.2019.00863
Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M, Dima D, Precup R, Tomuleasa C, Soverini S. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the . Front Oncol. 2019 Sep 23;9:863. doi: 10.3389/fonc.2019.00863. eCollection 2019. PMID: 31608223; PMCID: PMC6768007.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2019 Sep 23;9:863. doi: 10.3389/fonc.2019.00863. eCollection 2019.

Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the .

Frontiers in oncology

Vlad Moisoiu, Patric Teodorescu, Lorand Parajdi, Sergiu Pasca, Mihnea Zdrenghea, Delia Dima, Radu Precup, Ciprian Tomuleasa, Simona Soverini

Affiliations

  1. Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
  2. Department of Hematology, Ion Chiricuta Clinical Research Center, Cluj Napoca, Romania.
  3. Department of Mathematics, Babes Bolyai University, Cluj Napoca, Romania.
  4. Department of Hematology, Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
  5. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L. and A. Seràgnoli, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.

PMID: 31608223 PMCID: PMC6768007 DOI: 10.3389/fonc.2019.00863

Abstract

Chronic myelogenous leukemia (CML) is a malignancy of the myeloid cell lineage characterized by a recurrent chromosomal abnormality: the Philadelphia chromosome, which results from the reciprocal translocation of the chromosomes 9 and 22. The Philadelphia chromosome contains a fusion gene called BCR-ABL1. The BCR-ABL1 codes for an aberrantly functioning tyrosine kinase that drives the malignant proliferation of the founding clone. The advent of tyrosine kinase inhibitors (TKI) represents a landmark in the treatment of CML, that has led to tremendous improvement in the remission and survival rates. Since the introduction of imatinib, the first TKI, several other TKI have been approved that further broadened the arsenal against CML. Patients treated with TKIs require sensitive monitoring of BCR-ABL1 transcripts with quantitative real-time polymerase chain reaction (qRT-PCT), which has become an essential part of managing patients with CML. In this review, we discuss the importance of the BCR-ABL1 assay, and we highlight the growing importance of BCR-ABL1 dynamics. We also introduce a mathematical correction for the BCR-ABL1 assay that could help homogenizing the use of the ABL1 as a control gene. Finally, we discuss the growing body of evidence concerning treatment-free remission. Along with the continuous improvement in the therapeutic arsenal against CML, the molecular monitoring of CML represents the

Copyright © 2019 Moisoiu, Teodorescu, Parajdi, Pasca, Zdrenghea, Dima, Precup, Tomuleasa and Soverini.

Keywords: BCR-ABL; IS; chronic myeloid leukemia; mathematical modeling; treatment free remission

References

  1. Blood. 2016 Jun 2;127(22):2742-50 - PubMed
  2. J Clin Oncol. 2018 Jan 20;36(3):231-237 - PubMed
  3. Blood. 2008 Oct 15;112(8):3330-8 - PubMed
  4. Clin Cancer Res. 2006 Dec 15;12(24):7374-9 - PubMed
  5. Cancer Cell. 2014 Sep 8;26(3):428-442 - PubMed
  6. Blood. 2004 Oct 1;104(7):2204-5 - PubMed
  7. Cancer. 2009 Dec 1;115(23):5382-93 - PubMed
  8. Drugs. 2017 Jan;77(1):85-96 - PubMed
  9. Fundam Clin Pharmacol. 2013 Dec;27(6):690-7 - PubMed
  10. Best Pract Res Clin Haematol. 2001 Sep;14(3):553-71 - PubMed
  11. Blood. 2013 Oct 24;122(17):3086-8 - PubMed
  12. Leukemia. 2003 Dec;17(12):2474-86 - PubMed
  13. Leukemia. 2014 Oct;28(10):1988-92 - PubMed
  14. Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51 - PubMed
  15. J Clin Invest. 2007 Aug;117(8):2030-2 - PubMed
  16. N Engl J Med. 2006 Dec 7;355(23):2408-17 - PubMed
  17. Blood. 2009 Sep 3;114(10):2168-71 - PubMed
  18. Leuk Lymphoma. 2015 Feb;56(2):546-7 - PubMed
  19. J Clin Invest. 2011 Jan;121(1):396-409 - PubMed
  20. Cancer Cell. 2009 Nov 6;16(5):401-12 - PubMed
  21. Pathol Biol (Paris). 2009 Jul;57(5):388-91 - PubMed
  22. Haematologica. 2014 Mar;99(3):458-64 - PubMed
  23. Blood Adv. 2018 Nov 13;2(21):2922-2936 - PubMed
  24. Leukemia. 2015 Sep;29(9):1832-8 - PubMed
  25. Cancer. 2017 Nov 15;123(22):4391-4402 - PubMed
  26. Blood. 2016 Feb 11;127(6):666-7 - PubMed
  27. Blood. 2003 Jul 1;102(1):276-83 - PubMed
  28. Expert Rev Mol Diagn. 2013 Sep;13(7):749-62 - PubMed
  29. Methods Mol Biol. 2011;730:33-61 - PubMed
  30. J Clin Oncol. 2008 Jul 10;26(20):3358-63 - PubMed
  31. Expert Rev Hematol. 2016 May;9(5):419-24 - PubMed
  32. J Clin Oncol. 2012 Oct 1;30(28):3486-92 - PubMed
  33. J Clin Oncol. 2005 Jun 20;23(18):4100-9 - PubMed
  34. Blood. 2009 Feb 19;113(8):1619-30 - PubMed
  35. Clin Cancer Res. 2007 Oct 15;13(20):6136-43 - PubMed
  36. Blood. 2008 Dec 15;112(13):4839-42 - PubMed
  37. J Clin Oncol. 2012 Jan 20;30(3):232-8 - PubMed
  38. Chin Med J (Engl). 2009 Jun 20;122(12):1413-7 - PubMed
  39. N Engl J Med. 2017 Mar 9;376(10):917-927 - PubMed
  40. Blood. 2012 Jul 26;120(4):737-47 - PubMed
  41. Int J Hematol. 2012 Feb;95(2):209-13 - PubMed
  42. Blood. 2014 Feb 27;123(9):1309-18 - PubMed
  43. Clin Cancer Res. 2014 Jan 15;20(2):310-22 - PubMed
  44. Blood. 2016 Feb 11;127(6):703-12 - PubMed
  45. Curr Hematol Malig Rep. 2014 Mar;9(1):1-8 - PubMed
  46. Haematologica. 2013 Jul;98(7):e78-9 - PubMed
  47. Blood. 2008 Dec 1;112(12):4437-44 - PubMed
  48. Blood. 2014 Jul 24;124(4):511-8 - PubMed
  49. Blood. 2007 Apr 15;109(8):3496-9 - PubMed
  50. Am J Hematol. 2015 Apr;90(4):282-7 - PubMed
  51. Blood. 2009 Dec 3;114(24):4944-53 - PubMed
  52. Leuk Res. 2017 Jun;57:109-111 - PubMed
  53. J Mol Diagn. 2013 Sep;15(5):565-76 - PubMed
  54. PLoS One. 2014 Sep 09;9(9):e106250 - PubMed
  55. Br J Pharmacol. 2009 Oct;158(4):1153-64 - PubMed
  56. Leukemia. 2006 Jun;20(6):1061-6 - PubMed
  57. Leukemia. 2017 May;31(5):1108-1116 - PubMed
  58. Blood. 2008 Apr 15;111(8):4022-8 - PubMed
  59. Radiat Res. 2013 Mar;179(3):361-82 - PubMed
  60. J Clin Oncol. 2008 Oct 10;26(29):4806-13 - PubMed
  61. N Engl J Med. 2003 Mar 13;348(11):994-1004 - PubMed
  62. J Clin Oncol. 2002 Jan 1;20(1):214-20 - PubMed
  63. Leukemia. 2018 May;32(5):1222-1228 - PubMed
  64. Blood. 2012 Feb 9;119(6):1501-10 - PubMed
  65. Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94 - PubMed
  66. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100 - PubMed
  67. Leukemia. 2016 May;30(5):1044-54 - PubMed
  68. J Clin Oncol. 2009 Sep 1;27(25):4204-10 - PubMed
  69. Expert Rev Hematol. 2018 Apr;11(4):269-272 - PubMed
  70. Leukemia. 2016 Aug;30(8):1638-47 - PubMed
  71. Nat Med. 2006 Oct;12(10):1181-4 - PubMed
  72. Blood. 2017 Mar 2;129(9):1166-1176 - PubMed
  73. J Clin Oncol. 2016 Jul 10;34(20):2333-40 - PubMed
  74. N Engl J Med. 2003 Oct 9;349(15):1423-32 - PubMed
  75. Leukemia. 2017 Nov;31(11):2398-2406 - PubMed
  76. Ann Hematol. 2015 Apr;94 Suppl 2:S159-65 - PubMed
  77. Blood. 2004 Dec 1;104(12):3739-45 - PubMed
  78. Leukemia. 2012 Sep;26(9):2096-102 - PubMed
  79. Am J Hematol. 2016 Feb;91(2):252-65 - PubMed
  80. N Engl J Med. 2006 Jun 15;354(24):2542-51 - PubMed
  81. J Clin Oncol. 2011 Apr 20;29(12):1634-42 - PubMed
  82. Leukemia. 2017 Mar;31(3):585-592 - PubMed
  83. J Hematol Oncol. 2018 Jun 20;11(1):84 - PubMed
  84. Blood. 2008 Jul 1;112(1):53-5 - PubMed
  85. Blood. 2009 Sep 10;114(11):2232-5 - PubMed
  86. Blood. 2007 Jan 1;109(1):58-60 - PubMed

Publication Types